Anticoagulant Regimen for Elderly Patients with Impaired Renal Function

Patient Evaluation and Risk Factors

The European Society of Cardiology recommends that advanced age (83 years) and low body weight (55 kg) are important risk factors for bleeding under anticoagulants 1, 2
These characteristics correspond to two of the three criteria for dose reduction for apixaban (age ≥80 years and weight ≤60 kg) 1
Impaired renal function also increases the risk of bleeding with all direct oral anticoagulants (DOACs) 2, 3

The European Heart Society recommends apixaban at 2.5 mg twice daily for this patient because it meets two of the three dose reduction criteria (age ≥80 years and weight ≤60 kg) 1
Apixaban has the most favorable gastrointestinal safety profile among DOACs, particularly in patients over 75 years old 3, 4
The renal elimination of apixaban is the lowest among DOACs (only 27%), making it safer for patients with impaired renal function 3, 4

For moderate renal impairment (ClCr 30-49 mL/min), apixaban at 2.5 mg twice daily remains the preferred choice 1, 3
For severe renal impairment (ClCr 15-29 mL/min), apixaban may be used at 2.5 mg twice daily, but with caution 3, 6
For end-stage renal disease (ClCr <15 mL/min), DOACs are generally not recommended 1, 7

Evaluation of renal function before initiating treatment and at least annually thereafter is recommended by the European Heart Society 5
More frequent monitoring (2-3 times a year) is recommended for patients with moderate renal impairment 5
Attention to drug interactions, particularly in elderly patients who are often polymedicated, is crucial 2
Patient education on signs of bleeding and the importance of adherence to treatment is recommended by the European Heart Society 2, 3